Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | K(lysine) acetyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | acetyltransferase, GNAT family | 0.0047 | 0 | 0.5 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.0051 | 0.0075 | 0.5 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.0051 | 0.0075 | 0.5 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0051 | 0.0075 | 0.5 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.0047 | 0 | 0.5 |
Loa Loa (eye worm) | NNMT/PNMT/TEMT family protein | 0.031 | 0.4596 | 1 |
Brugia malayi | NNMT/PNMT/TEMT family protein | 0.031 | 0.4596 | 0.5632 |
Brugia malayi | Serotonin receptor | 0.0415 | 0.6429 | 1 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.017 | 0.2147 | 0.2088 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0051 | 0.0075 | 0.5 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0613 | 0.9889 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.031 | 0.4596 | 1 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0175 | 0.2233 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.031 | 0.4596 | 1 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.0051 | 0.0075 | 0.5 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.0047 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
Potency (functional) | 0.0029 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 5.6234 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.